CARB-X

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, a leading cause of death around the world. The CARB-X portfolio is the world’s most scientifically diverse, early development pipeline of new antibiotics, preventatives, rapid diagnostics and other products. CARB-X is the only global partnership that integrates solutions for the prevention, diagnosis, and treatment of life-threatening bacterial infections, translating innovation from basic research to first-in-human clinical trials. CARB-X is funded by a global consortium of governments and foundations. CARB-X is headquartered at Boston University, a major research university and a member of the prestigious Association of American Universities. CARB-X is a proud example of Boston University’s leadership, collaboration, and engagement to meet the needs of society: a global public-private partnership confronting one of the most serious threats to health and development worldwide. Our vision Life-saving innovation keeping the world prepared for dangerous bacterial infections. Our mission Accelerate a diverse portfolio of innovative antibacterial products towards clinical development and regulatory approval with funding, expert support, and portfolio acceleration tools.